Coadministration has not been studied but use of eletriptan is contraindicated within at least 72 hours of nirmatrelvir/ritonavir. Eletriptan is metabolized by CYP3A4 and is unlikely to cause clinically important drug interactions mediated by CYP enzymes. Nirmatrelvir/ritonavir is metabolized by CYP3A and inhibits CYP3A. Coadministration is expected to increase eletriptan concentrations. Coadministration of eletriptan within at least 72 hours of nirmatrelvir/ritonavir is contraindicated in the American product label for Paxlovid due to potential for serious adverse reactions including cardiovascular and cerebrovascular events. However, if deemed clinically appropriate to do so, wait at least 12 hours after the last eletriptan dose before starting nirmatrelvir/ritonavir. Given inhibition of CYP3A4 by nirmatrelvir/ritonavir take several days to resolve, resume eletriptan treatment 3 days after the last dose of nirmatrelvir/ritonavir.